ST Germain D J Co. Inc. Sells 117 Shares of ResMed Inc. (NYSE:RMD)

ST Germain D J Co. Inc. trimmed its holdings in shares of ResMed Inc. (NYSE:RMD) by 0.1% during the fourth quarter, HoldingsChannel reports. The fund owned 93,049 shares of the medical equipment provider’s stock after selling 117 shares during the quarter. ST Germain D J Co. Inc.’s holdings in ResMed were worth $21,279,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in RMD. True Wealth Design LLC grew its stake in shares of ResMed by 2,200.0% in the third quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 110 shares during the last quarter. Ashton Thomas Securities LLC acquired a new position in ResMed during the 3rd quarter worth about $34,000. Capital Performance Advisors LLP bought a new stake in shares of ResMed in the 3rd quarter valued at about $60,000. Quest Partners LLC increased its stake in shares of ResMed by 44.1% in the second quarter. Quest Partners LLC now owns 327 shares of the medical equipment provider’s stock valued at $63,000 after buying an additional 100 shares during the period. Finally, Quarry LP raised its position in shares of ResMed by 271.9% during the second quarter. Quarry LP now owns 331 shares of the medical equipment provider’s stock worth $63,000 after acquiring an additional 242 shares during the last quarter. 54.98% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at ResMed

In other news, Director Peter C. Farrell sold 2,000 shares of the firm’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $248.74, for a total transaction of $497,480.00. Following the completion of the sale, the director now directly owns 83,204 shares of the company’s stock, valued at $20,696,162.96. This trade represents a 2.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Witte Jan De sold 796 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $248.81, for a total transaction of $198,052.76. Following the completion of the transaction, the director now directly owns 6,723 shares in the company, valued at $1,672,749.63. This trade represents a 10.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 11,099 shares of company stock valued at $2,719,385. 0.71% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently commented on RMD shares. Baird R W upgraded ResMed to a “strong-buy” rating in a report on Tuesday, September 24th. KeyCorp upped their price objective on shares of ResMed from $251.00 to $266.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. Needham & Company LLC reissued a “hold” rating on shares of ResMed in a research note on Friday, October 25th. Stifel Nicolaus initiated coverage on shares of ResMed in a research report on Friday, December 13th. They set a “hold” rating and a $250.00 price target on the stock. Finally, Wolfe Research reiterated an “underperform” rating and set a $180.00 price target on shares of ResMed in a report on Wednesday, September 18th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $233.09.

ResMed Stock Down 0.8 %

ResMed stock traded down $1.86 during midday trading on Friday, reaching $234.31. The stock had a trading volume of 278,653 shares, compared to its average volume of 634,728. The company has a fifty day moving average price of $240.05 and a two-hundred day moving average price of $230.52. The company has a market capitalization of $34.40 billion, a P/E ratio of 31.03, a PEG ratio of 1.73 and a beta of 0.70. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13. ResMed Inc. has a 12 month low of $168.29 and a 12 month high of $260.49.

ResMed (NYSE:RMD) last posted its earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 EPS for the quarter, topping the consensus estimate of $2.03 by $0.17. The company had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.19 billion. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The firm’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the previous year, the firm posted $1.64 earnings per share. As a group, equities analysts expect that ResMed Inc. will post 9.34 EPS for the current fiscal year.

ResMed Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, December 12th. Investors of record on Thursday, November 7th were issued a dividend of $0.53 per share. The ex-dividend date of this dividend was Thursday, November 7th. This represents a $2.12 annualized dividend and a yield of 0.90%. ResMed’s dividend payout ratio (DPR) is currently 28.08%.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.